These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24 related articles for article (PubMed ID: 17238848)
1. Plasmapheresis therapy in renal transplant patients: five-year experience. Gungor O; Sen S; Kircelli F; Yilmaz M; Sarsik B; Ozkahya M; Hoscoskun C; Ok E; Toz H Transplant Proc; 2011 Apr; 43(3):853-7. PubMed ID: 21486614 [TBL] [Abstract][Full Text] [Related]
2. A Machine Learning Analysis of Prognostic Genes Associated With Allograft Tolerance After Renal Transplantation. Li Z; Lu Z; Hu C; Zhang Y; Chen Y; Zhang J; Guo F; Wang J; Tang Z; Tang F; He Z Cell Transplant; 2023; 32():9636897231195116. PubMed ID: 37650419 [TBL] [Abstract][Full Text] [Related]
3. Role of therapeutic plasma exchange in acute humoral rejection patients undergoing live-related renal transplantation: A single-center experience. Kakkar B; Makroo RN; Agrawal S; Chowdhry M; Nayak S; Jasuja S; Sagar G; Guleria S Asian J Transfus Sci; 2021; 15(1):62-67. PubMed ID: 34349459 [TBL] [Abstract][Full Text] [Related]
5. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Rocha PN; Butterly DW; Greenberg A; Reddan DN; Tuttle-Newhall J; Collins BH; Kuo PC; Reinsmoen N; Fields T; Howell DN; Smith SR Transplantation; 2003 May; 75(9):1490-5. PubMed ID: 12792502 [TBL] [Abstract][Full Text] [Related]
6. Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: experience in renal allograft transplantation. Lehrich RW; Rocha PN; Reinsmoen N; Greenberg A; Butterly DW; Howell DN; Smith SR Hum Immunol; 2005 Apr; 66(4):350-8. PubMed ID: 15866697 [TBL] [Abstract][Full Text] [Related]
7. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation. Ibernón M; Gil-Vernet S; Carrera M; Serón D; Moreso F; Bestard O; Cruzado JM; Grinyó JM Transplant Proc; 2005 Nov; 37(9):3743-5. PubMed ID: 16386524 [TBL] [Abstract][Full Text] [Related]
8. Plasmapheresis as rescue therapy in accelerated acute humoral rejection. Abraham KA; Brown C; Conlon PJ; Donohoe J; Hickey DP; O'Neill D; Keogan MT; Dorman AM; Walshe J J Clin Apher; 2003; 18(3):103-10. PubMed ID: 14569599 [TBL] [Abstract][Full Text] [Related]
9. Radiotherapy for rejection of renal transplant allografts refractory to medical immunosuppression. Wahl AO; Small W; Dixler I; Strom S; Rademaker A; Leventhal J; Abecassis MM Am J Clin Oncol; 2006 Dec; 29(6):551-4. PubMed ID: 17148990 [TBL] [Abstract][Full Text] [Related]
10. Plasmapheresis in the treatment of early acute kidney allograft dysfunction. Nafar M; Farrokhi F; Hemati K; Pour-Reza-Gholi F; Firoozan A; Einollahi B Exp Clin Transplant; 2006 Dec; 4(2):506-9. PubMed ID: 17238848 [TBL] [Abstract][Full Text] [Related]
11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
12. Use of renin-angiotensin-aldosterone system inhibitors within the first eight to twelve weeks after renal transplantation. Jennings DL; Taber DJ Ann Pharmacother; 2008 Jan; 42(1):116-20. PubMed ID: 18094340 [TBL] [Abstract][Full Text] [Related]